A drug screen is a laboratory analysis of a biological sample, most often urine, that detects the presence of specific drugs or their byproducts in your body. It’s the standard method employers, courts, medical providers, and government agencies use to determine whether someone has recently used certain substances. Most screens follow a two-step process: a fast initial screening that flags potential positives, followed by a more precise confirmatory test if anything comes up.
How the Two-Step Process Works
The first step uses a technique called immunoassay, which relies on antibodies that react to broad categories of drugs. It’s fast, inexpensive, and can be run on simple test cups or dipsticks right at the collection site. The tradeoff is precision. Immunoassay can’t identify the exact substance in your sample. It groups drugs into families like “amphetamines” or “opioids” and flags anything above a set concentration threshold.
If the initial screen comes back positive, the sample moves to confirmatory testing. This second step uses a technology called mass spectrometry, often paired with either gas or liquid chromatography. These instruments separate and identify individual molecules, pinpointing exactly which drug is present and at what concentration. Mass spectrometry is considered the gold standard in toxicology because of its high specificity and reproducibility. A result isn’t reported as a true positive until it passes this confirmation step.
What a Standard Panel Tests For
The most common version is the 5-panel drug screen, which is the standard for all U.S. Department of Transportation testing and most federal workplace programs. It covers five drug categories: marijuana (THC), cocaine, amphetamines, opioids, and PCP. Despite being called “5-panel,” it actually confirms 14 individual substances when you break the categories down. The amphetamines group includes methamphetamine, MDMA, and MDA. The opioids group covers codeine, morphine, heroin (via a unique metabolite called 6-AM), hydrocodone, hydromorphone, oxycodone, and oxymorphone. Federal guidelines added fentanyl testing as well.
Expanded panels (7, 10, or 12-panel) add categories like benzodiazepines, barbiturates, methadone, and buprenorphine. These are more common in pain management clinics, substance use treatment programs, and court-ordered testing. Your employer or ordering provider chooses the panel based on the situation.
Cut-Off Levels and What They Mean
A drug screen doesn’t simply report “drug found” or “no drug found.” Each substance has a cut-off concentration, measured in nanograms per milliliter (ng/mL), and anything below that threshold is reported as negative even if trace amounts are present. Federal guidelines set these cut-offs to reduce the chance of a positive result from passive or incidental exposure.
For urine, the initial screening cut-off for marijuana metabolites is 50 ng/mL. Cocaine metabolites sit at 150 ng/mL, amphetamines at 500 ng/mL, and codeine or morphine at 2,000 ng/mL. Fentanyl has the lowest cut-off at just 1 ng/mL, reflecting how potent it is in small quantities. Oral fluid (saliva) testing uses much lower thresholds across the board because drug concentrations in saliva are naturally lower than in urine.
Specimen Types and Detection Windows
Urine is by far the most common specimen for drug screening because it’s accurate, reliable, and cheap to process. Most drugs remain detectable in urine for one to four days after use. Cocaine, for example, is typically detectable for two to four days, while amphetamines and most opioids show up for one to two days. Marijuana is the notable exception: a single use may clear in one to three days, but chronic, heavy use can remain detectable for up to 30 days because THC stores in body fat.
Hair testing offers a much longer detection window, potentially months or even years, since drug traces become embedded in the hair shaft as it grows. It’s useful when a longer history of use matters, but it costs more and some people can’t provide a sample of sufficient length. Blood and saliva testing detect drugs for the shortest window, typically hours to a few days, making them better suited for determining very recent use, such as after a workplace accident.
False Positives and Cross-Reactivity
Because immunoassay works by recognizing molecular shapes rather than exact chemical identities, certain medications can trigger a positive result even when you haven’t used an illicit drug. This is called cross-reactivity, and false positives for amphetamines are the most commonly reported type.
A surprisingly long list of everyday medications can cause this. Over-the-counter cold medicines containing dextromethorphan or diphenhydramine, the pain relievers ibuprofen and naproxen, the antidepressants bupropion, sertraline, trazodone, and venlafaxine, the heartburn medication ranitidine, and even some nonprescription nasal inhalers have all been documented to produce false-positive results. Other reported triggers include the antipsychotic quetiapine (which can falsely flag for PCP) and certain antibiotics. This is one of the main reasons confirmatory testing exists. If your initial screen comes back positive and you believe it’s wrong, the confirmatory step using mass spectrometry will distinguish the medication you’re taking from an illicit substance.
What Happens After a Positive Result
In regulated workplace testing, a positive confirmatory result doesn’t go straight to your employer. It first goes to a Medical Review Officer (MRO), a licensed physician trained specifically in drug testing interpretation. The MRO’s job is to contact you for a verification interview and determine whether there’s a legitimate medical explanation for the result. If you have a valid prescription for the substance that was detected, you present that information to the MRO, who then verifies its authenticity. A confirmed opioid result in someone with a legitimate prescription for oxycodone, for instance, would be reported as negative to the employer.
Federal regulations require the MRO to give you the opportunity to explain the result in every case. If the medication you’re prescribed could pose a safety concern for your job, you’re given five business days to work with your prescribing doctor to explore alternatives before any third party is notified about the specific medication. The MRO does not question whether your doctor should have prescribed the substance in the first place.
The Collection Process
For a federally regulated urine drug screen, the collection follows a strict chain-of-custody procedure designed to prevent tampering and ensure the result holds up legally. A trained collector verifies your identity, gives you a collection container, and checks the specimen temperature within four minutes of receiving it to confirm it came from your body. The collector inspects the sample for unusual color, odor, or foreign material, verifies the volume is sufficient, then pours it into labeled specimen bottles while you watch.
You initial the labels on the sealed bottles. The collector completes documentation on a Custody and Control Form, places the sealed bottles in a leak-proof bag with the paperwork, and ships everything to a certified laboratory. Every person who handles the specimen signs off on the chain of custody, creating an unbroken record from collection to final result. Most regulated collections are split specimens, meaning the sample is divided into two bottles so a second test can be run if you challenge the result.
Dilute Results
Sometimes a drug screen comes back “negative dilute,” meaning no drugs were detected but the urine was more watered-down than normal. Laboratories flag this based on creatinine concentration, a natural waste product your kidneys filter at a fairly consistent rate. The average normal urine creatinine level is around 130 mg/dL. A sample with creatinine below 20 mg/dL is considered dilute.
Dilution can happen innocently if you drank a lot of water before the test. It can also be intentional, since flooding your system with fluids lowers the concentration of drug metabolites and may push them below the cut-off threshold. Many employers and courts require a retest after a dilute result. In court-supervised testing programs, patterns matter: if you produce normal creatinine levels most of the time but occasionally submit very dilute samples, that pattern can be treated as a relapse indicator regardless of whether the screen itself was negative.